sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
emerg
respect
shown
caus
new
coronaviru
cov
design
sarscov
merscov
sar
epidem
brought
control
use
infect
control
method
continu
outbreak
vaccin
mer
urgent
need
preclin
evalu
inactiv
subunit
wholeviru
vaccin
sar
elicit
serum
neutral
antibodi
protect
infect
monkey
ferret
mice
challeng
infecti
sarscov
howev
challeng
anim
exhibit
immunopathologictyp
lung
reaction
result
led
safeti
concern
rel
sarscov
moreov
due
appar
epidemiolog
control
sar
along
find
clinic
trial
sarscov
vaccin
place
hold
rise
mer
decid
revisit
vaccin
prepar
sar
studi
initi
prepar
small
batch
whole
inactiv
viru
wiv
evalu
began
test
determin
vaccin
inactiv
merscov
vaccin
would
result
immunopatholog
vaccin
host
similar
seen
sarscov
mous
model
studi
merscov
initi
avail
sinc
mice
small
anim
lack
merscov
receptor
reason
develop
transgen
mous
model
contain
human
avail
model
provid
opportun
assess
whether
inactiv
merscov
vaccin
would
induc
protect
merscov
infect
also
induc
eosinophilcontain
pulmonari
immunopatholog
similar
sarscov
vaccin
first
report
similar
risk
immunopatholog
appear
exist
merscovinactiv
vaccin
despit
abil
protect
infect
wiv
stock
prepar
gamma
irradi
megarad
aliquot
vero
cellfre
merscov
inactiv
supernat
neg
rigor
isol
test
subject
polyethylen
glycolsalt
precipit
purifi
sucros
densiti
dilut
pb
equival
western
blot
analysi
use
rabbit
antimerscov
antibodi
demonstr
viru
structur
protein
includ
surfac
protein
nucleoprotein
data
shown
assess
immunogen
protect
efficaci
wiv
well
potenti
elicit
immunopatholog
upon
live
viru
challeng
vaccin
anim
group
six
transgen
mice
immun
intramuscularli
im
twice
three
week
apart
mice
receiv
wiv
wiv
adjuv
alhydrogel
alum
invivogen
alum
accord
protocol
approv
iacuc
committe
univers
texa
medic
branch
sera
collect
day
second
immun
microneutr
antibodi
test
mice
challeng
intranas
sacrif
day
group
day
assess
lung
viral
load
vero
infect
quantit
q
pcr
assay
target
upe
gene
merscov
lung
cytokin
transcript
profil
qrtpcr
assay
previous
addit
deparaffin
section
stain
either
routin
hematoxylinandeosin
h
e
histopatholog
evalu
antibodi
specif
eosinophil
major
basic
protein
mbp
provid
lee
laboratori
confirm
eosinophil
infiltr
figur
show
neither
adjuv
alon
group
develop
detect
neutral
antibodi
wherea
vaccin
group
develop
significantli
greater
neutral
antibodi
respons
group
adjuv
alon
p
mean
titer
higher
wivalum
group
p
consist
absenc
specif
antibodi
respons
infecti
viru
readili
detect
lung
three
infect
anim
immun
alum
group
avail
day
averag
respect
limit
detect
lod
vero
cellbas
infect
assay
contrast
infecti
viru
remain
undetect
vaccin
group
either
time
fig
titer
viral
rna
reveal
qrtpcr
assay
express
equival
also
compar
among
group
group
exhibit
detect
viral
rna
fig
titer
lower
vaccin
group
day
none
significantli
lower
control
fig
howev
titer
vaccin
group
day
significantli
lower
either
adjuv
group
p
fig
titer
group
also
significantli
lower
either
vaccin
group
p
gross
patholog
note
either
day
data
shown
howev
histopatholog
note
group
day
sever
scale
none
mild
moder
sever
h
estain
sampl
alum
group
grade
day
mononuclear
cell
infiltr
includ
lymphocyt
macrophagesmonocyt
vaccin
group
grade
day
tabl
lung
section
similarli
score
eosinophil
infiltr
shown
figur
left
eosinophil
mbp
brown
detect
peribronchiolar
space
alum
day
alveolar
wall
day
level
eosinophil
infiltr
similar
reveal
infect
mice
without
prior
manipul
score
howev
moder
level
score
eosinophil
infiltr
peribronchiolar
perivascular
space
could
readili
observ
day
fig
right
spread
alveoli
mice
day
pi
vaccin
group
data
shown
pulmonari
cytokin
profil
vaccin
challeng
mice
perform
use
qrtpcr
small
number
anim
test
cytokin
assay
perform
twice
day
pattern
similar
test
signific
differ
test
fig
cytokin
activ
seen
adjuv
group
significantli
differ
uninfect
anim
howev
signific
increas
seen
cytokin
test
vaccin
group
notabl
increas
cytokin
associ
hypersensit
reaction
includ
eosinophil
cytokin
level
lower
vaccin
group
day
significantli
greater
uninfect
howev
significantli
increas
wiv
group
p
data
shown
studi
conduct
test
whether
inactiv
merscov
vaccin
would
induc
neutral
antibodi
protect
merscov
infect
yet
lead
hypersensitivitytyp
lung
immunopatholog
reaction
eosinophil
infiltr
challeng
infecti
viru
seen
sarscovinactiv
result
suggest
similar
risk
exist
inactiv
merscov
vaccin
vaccin
lot
size
requir
transgen
mice
limit
studi
group
size
concern
immununogen
includ
adjuv
group
sinc
adjuv
report
induc
superior
antibodi
respons
compar
adjuv
merscov
receptorbind
domain
rbd
proteinbas
serum
neutral
antibodi
protect
infect
found
vaccin
alon
adjuv
group
also
exhibit
hypersensitivitytyp
lung
reaction
challeng
includ
increas
patholog
eosinophil
infiltr
immun
reaction
lead
eosinophil
infiltr
consid
hypersensit
reaction
respons
mediat
via
notabl
cytokin
promot
eosinophil
infiltr
found
associ
lung
vaccin
challeng
anim
provid
support
vaccinationrel
hypersensit
concept
support
attribut
immunopatholog
immun
respons
provid
immun
inactiv
sarscov
vaccin
adjuv
studi
mice
inactiv
sarscov
vaccin
given
adjuv
exhibit
similar
immunopatholog
reaction
viru
find
merscov
vaccin
similar
find
sarscov
vaccin
reminisc
report
mice
given
formalininactiv
wholeviru
respiratori
syncyti
viru
rsv
vaccin
challeng
infecti
protect
infect
occur
despit
increas
histopatholog
similar
rsv
vaccin
given
infant
led
increas
pulmonari
diseas
sever
compon
vaccin
led
immunopatholog
identifi
suggest
viral
compon
well
contamin
formalin
effect
howev
immunopatholog
sarscov
vaccin
occur
wholeviru
vaccin
subunit
vaccin
differ
inactiv
method
differ
prepar
substrat
recombin
surfac
protein
experi
may
indic
respons
compon
sar
merscov
vaccin
viral
result
studi
vector
vaccin
point
nucleoprotein
n
protein
respons
immunopatholog
effect
seen
indic
protein
might
free
risk
howev
rs
protein
induc
identifi
remedi
specif
basi
immunopatholog
would
facilit
vaccin
trial
human
implic
current
studi
applic
inactiv
merscov
vaccin
prevent
mer
human
may
carri
risk
lung
immunopatholog
subsequ
expos
merscov
studi
also
lead
us
suggest
extens
background
preclin
experi
inactiv
sarscov
vaccin
may
applic
inactiv
merscov
vaccin
major
limit
current
studi
small
number
anim
evalu
reduc
strength
find
nevertheless
find
seem
clear
risk
similar
sarscov
vaccin
exist
merscov
vaccin
addit
data
support
belief
immunopatholog
repres
respons
also
occur
merscov
vaccin
sarscov
vaccin
contempl
futur
studi
